Design Therapeutics, Inc. (DSGN) News
Filter DSGN News Items
DSGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DSGN News From Around the Web
Below are the latest news stories about DESIGN THERAPEUTICS INC that investors may wish to consider to help them evaluate DSGN as an investment opportunity.
Design Therapeutics to Participate in Multiple Upcoming Investor ConferencesCARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: 2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK Piper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3, |
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM PortfolioFuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Se |
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. By way of example, Design... |
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics StockIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceCARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The |
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a BetThe consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investorsKey Insights Institutions' substantial holdings in Design Therapeutics implies that they have significant influence... |
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ PortfolioFriedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Cash and Securities of $261.0 Million Supports Operations Through Potentially Four Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments |
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit GainsBiotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:PIPR) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. Piper Sandler may be the best bet for investors especially when you see |
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic ReviewInsights on Financial Performance and Future Milestones |